Compare Stocks: DMRA, CRSP, COGT, and PTCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$31.86 -1.4%	$36.58	$13.72 ▼ $43.73	$5.61B	0.31	1.93 million shs	2.21 million shs
CRSP CRISPR Therapeutics	$54.09 -0.3%	$53.90	$44.12 ▼ $78.48	$5.24B	1.76	1.55 million shs	1.27 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$20.75 +0.4%	$28.18	$3.50 ▼ $38.33	$1.28B	1.46	782,195 shs	514,944 shs
PTCT PTC Therapeutics	$65.95 +5.2%	$70.49	$58.90 ▼ $90.87	$5.23B	0.55	1.13 million shs	1.91 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	0.00%	+2.57%	-6.81%	-16.60%	+128.18%
CRSP CRISPR Therapeutics	0.00%	-4.12%	-6.05%	-3.76%	-12.06%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-8.54%	-28.76%	-14.66%	+368.48%
PTCT PTC Therapeutics	0.00%	-4.13%	-10.59%	-23.17%	+6.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$31.86 -1.4%	$36.58	$13.72 ▼ $43.73	$5.61B	0.31	1.93 million shs	2.21 million shs
CRSP CRISPR Therapeutics	$54.09 -0.3%	$53.90	$44.12 ▼ $78.48	$5.24B	1.76	1.55 million shs	1.27 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$20.75 +0.4%	$28.18	$3.50 ▼ $38.33	$1.28B	1.46	782,195 shs	514,944 shs
PTCT PTC Therapeutics	$65.95 +5.2%	$70.49	$58.90 ▼ $90.87	$5.23B	0.55	1.13 million shs	1.91 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	0.00%	+2.57%	-6.81%	-16.60%	+128.18%
CRSP CRISPR Therapeutics	0.00%	-4.12%	-6.05%	-3.76%	-12.06%
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-8.54%	-28.76%	-14.66%	+368.48%
PTCT PTC Therapeutics	0.00%	-4.13%	-10.59%	-23.17%	+6.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	61.82% Upside
CRSP CRISPR Therapeutics	2.59	Moderate Buy	$67.94	25.61% Upside
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$46.50	124.10% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$99.08	50.24% Upside

Current Analyst Ratings Breakdown

Latest DMRA, CRSP, COGT, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	DMRA Damora Therapeutics, Inc. Common Stock	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
9/22/2026	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$130.00 ➝ $137.00
9/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/16/2026	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$55.00
9/15/2026	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
9/14/2026	DMRA Damora Therapeutics, Inc. Common Stock	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	PTCT PTC Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform	$98.00
9/1/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
CRSP CRISPR Therapeutics	$3.51M	1,490.02	N/A	N/A	$20.17 per share	2.68
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
PTCT PTC Therapeutics	$1.73B	3.18	$9.24 per share	7.14	($2.56) per share	-25.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	32.01	1.93	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)

Latest DMRA, CRSP, COGT, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	0.48	13.57	13.57
CRSP CRISPR Therapeutics	0.34	17.85	17.85
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
PTCT PTC Therapeutics	N/A	3.39	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
CRSP CRISPR Therapeutics	69.20%
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	6.59%
CRSP CRISPR Therapeutics	5.20%
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
PTCT PTC Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	258	173.52 million	162.09 million	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable

DMRA, CRSP, COGT, and PTCT Headlines

Recent News About These Companies

PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7% - Here's What Happened

September 28 at 2:59 PM | marketbeat.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 25 at 4:30 PM | prnewswire.com

Head-To-Head Analysis: Zealand Pharma A/S (OTCMKTS:ZLDPF) & PTC Therapeutics (NASDAQ:PTCT)

September 24, 2026 | americanbankingnews.com

PTC Therapeutics, Inc.: PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 22, 2026 | finanznachrichten.de

PTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4

September 22, 2026 | rttnews.com

Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00

September 22, 2026 | marketbeat.com

PTC Therapeutics acquires Fabry disease gene therapy from Sangamo

September 21, 2026 | streetinsider.com

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 21, 2026 | prnewswire.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells $671,200.00 in Stock

September 21, 2026 | americanbankingnews.com

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

September 20, 2026 | finance.yahoo.com

PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 10,000 Shares

September 19, 2026 | insidertrades.com

Bank of America Corp DE Takes $118.46 Million Position in PTC Therapeutics, Inc. $PTCT

September 19, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Strong-Buy at Wall Street Zen

September 19, 2026 | americanbankingnews.com

Wall Street Zen Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Strong-Buy"

September 19, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares

September 18, 2026 | marketbeat.com

PTC Therapeutics, Inc. (PTCT)

September 18, 2026 | finance.yahoo.com

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

PTC Therapeutics, Inc. $PTCT Shares Sold by Engineers Gate Manager LP

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Lowers Holdings in PTC Therapeutics, Inc. $PTCT

September 15, 2026 | marketbeat.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 15, 2026 | marketbeat.com

Leerink Partners Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)

September 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, CRSP, COGT, and PTCT Company Descriptions

Cogent Biosciences NASDAQ:COGT

$31.86 -0.45 (-1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$32.08 +0.22 (+0.67%)

As of 07:39 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$54.09 -0.14 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$54.51 +0.42 (+0.77%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$20.75 +0.09 (+0.44%)

As of 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

PTC Therapeutics NASDAQ:PTCT

$65.95 +3.28 (+5.23%)

Closing price 04:00 PM Eastern

Extended Trading

$65.92 -0.03 (-0.04%)

As of 07:30 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, CRSP, COGT, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, CRSP, COGT, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, CRSP, COGT, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, CRSP, COGT, and PTCT Company Descriptions

Cogent Biosciences NASDAQ:COGT

CRISPR Therapeutics NASDAQ:CRSP

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, CRSP, COGT, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, CRSP, COGT, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, CRSP, COGT, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, CRSP, COGT, and PTCT Company Descriptions

Cogent Biosciences NASDAQ:COGT

CRISPR Therapeutics NASDAQ:CRSP

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools